Phase 1 Study of Replication Competent Reovirus (Reolysin) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors

Trial Profile

Phase 1 Study of Replication Competent Reovirus (Reolysin) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors

Suspended
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Pelareorep (Primary) ; Sargramostim (Primary)
  • Indications Astrocytoma; Brain cancer; Glioblastoma; Glioma; Medulloblastoma; Neuroectodermal tumours; Oligodendroglioma; Rhabdoid tumour
  • Focus Adverse reactions
  • Most Recent Events

    • 11 Oct 2017 Status changed from recruiting to suspended.
    • 03 May 2016 Status changed from suspended to recruiting.
    • 11 Mar 2016 Based on investigator reply, totally 3 patients till date were accrued. Presently this trial is temporarily closed in order to adjust the dosing. FDA has approved for the changes and company is working on completing the internal approval process and start accrual by April 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top